What BioXtek does

BioXtek is a Pompano Beach, Florida-based regenerative therapeutics manufacturer founded in 2022 that develops biologic products derived from qualified single-birth placental and umbilical cord donors. The company operates an 11,000 sqft FDA-registered, AATB-accredited, cGMP/cGTP-compliant facility with ISO-rated cleanrooms and SAL 10⁻⁶ terminal sterilization capability, producing placental membrane patches (Sanoplast DHAAM, Sanoplast Duo), umbilical cord products (Sanoplast UAP, CordGuardECM), stem cell therapeutics (BioXcells in 10M and 25M cell vials), exosome therapeutics (BioXsomes), and a cosmetic serum (BioXjel+). At the core is the proprietary BioPūr Process, which preserves bioactive molecules including exosomes, growth factors, peptides, cytokines, miRNA, and the HC-HA/PTX3 complex while stripping endotoxins and immunogenic triggers from a cell-free extracellular matrix.

BioXtek commercializes through a sales-led GTM motion combining direct sales and a distributor network to reach healthcare providers, surgeons, pain management specialists, longevity clinics, and medi-spas across multiple U.S. states, with state-level tissue banking licensure secured in Florida, Delaware, Oregon, California, Illinois, Maryland, and New York. The company monetizes via one-time product sales (pricing undisclosed) with documented clinical outcomes including a 4x reduction in postoperative atrial fibrillation (8.3% vs 35.2%), 90% chronic wound healing at 12 weeks, and VAS pain score improvement from 8.2 to 2.3. In April 2026, BioXtek signed a non-binding LOI with Exo-Top Inc., the U.S. subsidiary of NurExone Biologic, to explore contract manufacturing and commercialization of bone marrow-derived MSC exosomes targeting the projected $1.6B+ regenerative aesthetics market by 2034 and potentially supporting NurExone's ExoPTEN clinical program.

The company is privately held as BioXtek LLC, employs 11-50 people, and is led by CEO Bruce Werber (board-certified reconstructive surgeon, 35+ years), Co-Founder Terrell Suddarth, CFO/COO Carmen Kerschbaum (12+ years at Pfizer and Roche), Commercial Lead Linda Liguore (former Repicon founder, scaled to $21M), and Medical Director Michael J. Bauer, with academic advisors from University of Arizona and Tulane. Revenue is not publicly disclosed; reimbursement depends on Medicare and private payer coverage policies for HCT/P products.

Name

BioXtek

Legal name

BioXtek LLC

Website

https://bioxtek.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

BioXtek is a Pompano Beach, FL-based regenerative therapeutics manufacturer founded in 2022 that uses its proprietary BioPūr Process to produce FDA-registered placental membrane patches, stem cell, and exosome products sold to healthcare providers, surgeons, and medi-spas across multiple U.S. states.

Ownership category

akta.pro rank

Product category

Regenerative Biologics Manufacturing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)

akta.pro secondary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Regenerative therapeutics
• Placental tissue products
• Biologic manufacturing
• Exosome therapeutics
• Wound care solutions

Headquarters

HQ city

Pompano Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Placental Membrane Patches: Sale of placental membrane patches (Sanoplast ECM, Sanoplast Duo) as FDA 1271/361 HCT/P products. Available in multiple configurations from single layer to quad layer, sized from 2x2cm to 15x20cm.
2. Umbilical Cord Products: Sale of umbilical cord derived products including Sanoplast UAP (human umbilical cord powder) and CordGuardECM (human umbilical cord patches) for wound care and tissue support applications.
3. Stem Cell and Exosome Therapeutics: Sale of BioXcells stem cell products (10M and 25M cell vials with 90% viability guaranteed) and BioXsomes exosome therapeutics for Florida physicians to treat Pain, Wounds, and Orthopedic complaints.
4. Cosmetic Products (BioXjel+):

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

BioXtek develops and manufactures biologic regenerative products derived from human placental and umbilical cord tissue. Its portfolio includes placental membrane patches (Sanoplast DHAAM), umbilical cord patches and powder (CordGuardECM, Sanoplast UAP), stem cell vials (BioXcells), exosome therapeutics (BioXsomes), and a topical cosmetic serum (BioXjel+). Products are manufactured at an FDA-registered, AATB-accredited 11,000 sqft cGMP facility using the proprietary BioPür Process and sold to physicians, surgeons, longevity clinics, and medi-spas.

Differentiator

Problem solved

Functional benefit

Brands

• Sanoplast DHAAM: Dehydrated and/or lyophilized placental membrane patches registered as FDA 1271/361 barriers and covers.
• BioXsomes
• BioXjel+
• BioXcells
• BioPür Process
• CordGuardECM
• Sanoplast UAP

Products and services

• Sanoplast DHAAM (Dehydrated Human Amniotic Membrane) Dehydrated and/or lyophilized placental membrane patches available in single to quad layer configurations sized from 2x2cm to 15x20cm, registered as FDA 1271/361 HCT/P products for wound care, surgical applications, dura replacement, tendon/nerve repair, and cardiac surgery. Sold to healthcare providers and surgeons.
• BioXsomes Fluid implantable acellular exosome therapeutic product sold to Florida-licensed physicians for treating pain, wounds, and orthopedic complaints.
• BioXjel+ Topical cosmetic serum derived from Wharton's jelly and amniotic fluid for facial aesthetics, hair aesthetics, topical scar application, and collagen stimulation. Sold to longevity clinics, medi-spas, and licensed professionals.
• BioXcells Stem cell product available in 10M and 25M cell vials with 90% viability guaranteed, offered to Florida physicians for pain, wounds, and orthopedic complaints.
• CordGuardECM Human umbilical cord patches for wound care and tissue support applications. Sold to healthcare providers.
• Sanoplast UAP Human umbilical cord powder product for wound care and tissue support applications. Sold to healthcare providers.

Quantifiable outcome

• 4x reduction in postoperative atrial fibrillation (POAF) incidence: 8.3% vs 35.2% (p=0.0136) in cardiac surgery pilot study
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Exo-Top Inc. (NurExone Biologic subsidiary)coreStrategic or Co-development Partner · 7 April 2026Exo-Top Inc., the U.S. subsidiary of NurExone Biologic Inc., signed a non-binding Letter of Intent with Florida-based BioXtek Inc. on April 7, 2026 to explore a strategic partnership for manufacturing and commercializing bone marrow-derived mesenchymal stem cell exosomes. The collaboration aims to combine Exo-Top's proprietary Master Cell Bank and exosome production expertise with BioXtek's U.S. GMP manufacturing infrastructure to support clinical supply and expand production capacity. The partnership targets the rapidly growing exosome-based regenerative aesthetics market projected to surpass $1.6 billion by 2034, and may also support clinical trials for NurExone's lead drug candidate ExoPTEN targeting acute spinal cord injury and optic nerve damage.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Organogenesis: Organogenesis manufactures and commercializes regenerative wound care biologics (Apligraf, Dermagraft, PuraPly) and surgical biologics (NuCel) — overlapping with BioXtek's placental membrane and umbilical cord product lines in the same HCT/P/commercial biologics category.
• MiMedx Group: MiMedx is the largest U.S. marketer of dehydrated amniotic membrane allografts (EpiFix, AmnioFix) for wound care and surgical applications — directly competing with BioXtek's Sanoplast placental membrane patches across the same physician channels and HCT/P regulatory pathway.

Emerging players

• Celularity: Celularity develops placental-derived cellular and regenerative therapies, leveraging the same birth-tissue donor model as BioXtek. Direct overlap in placental-derived biologics for wound care and aesthetics applications.
• NurExone Biologic: NurExone Biologic is the publicly-listed parent of Exo-Top, BioXtek's announced LOI partner. NurExone develops exosome-based therapeutics for spinal cord and optic nerve injury — sharing BioXtek's exosome manufacturing focus and serving as both a strategic partner and emerging exosome peer.
• Vericel: Vericel develops and commercializes autologous cell therapies (MACI for cartilage repair, Epicel for burns) — sharing BioXtek's regenerative medicine orientation, surgical biologics channel, and orthopedics/burn indications.
• Direct Biologics: Direct Biologics develops bone marrow-derived mesenchymal stem cell and exosome products for orthopedic, wound, and inflammatory indications — sharing BioXtek's MSC-derived exosome focus and competing for the same Florida aesthetics and orthopedic accounts.

Broad incumbents

• Smith+Nephew: Smith+Nephew is a large diversified wound care and orthopedics incumbent offering skin substitutes, advanced wound dressings, and regenerative solutions — competing with BioXtek in wound care while also serving as a benchmark for sales/distribution scale in the same end markets.
• Integra LifeSciences: Integra LifeSciences markets regenerative wound care and dural repair products (DuraGen, Integra Dermal Regeneration Template) — directly overlapping BioXtek's dura replacement and wound healing indications with a broader surgical specialty portfolio.
• Osiris Therapeutics (Smith+Nephew): Osiris was a pioneer in mesenchymal stem cell products (Grafix, OvationOS) for wound care and orthopedics, now part of Smith+Nephew — overlapping BioXtek's stem cell and placental-derived approaches in the same physician channels.
• Stryker: Stryker is a large medtech incumbent with orthopedics, surgical, and wound care portfolios that compete broadly with BioXtek's orthopedic and surgical applications of placental membrane patches.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/bioxtek

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioXtek